McKesson Corporation
 (MCK)

- NYSE
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Jun. 9, 2014, 5:51 PM
    | Jun. 9, 2014, 5:51 PM
  • May 28, 2014, 4:22 PM
    • McKesson Corporation (MCK) declares $0.24/share quarterly dividend, in line with previous.
    • Forward yield 0.53%
    • Payable July 1; for shareholders of record June 9; ex-div June 5.
    | May 28, 2014, 4:22 PM | 1 Comment
  • May 12, 2014, 5:52 PM
    • McKesson (MCK +1.9%) fiscal Q4 revenues: $38.1B (+24.9%); operating income: $556M (-13.8%); EPS from continuing ops: $1.56 (+40.5%). cash & equiv: $4.2B (+68%).
    • Full year: revenues: $137.6B (+12.7%); operating income: $2.4B (+4.3%); EPS from continuing ops: $5.93 (+3.3%); CF Ops: $3.1B (+24%).
    • F15 guidance: adjusted earnings/diluted share: $10.40 - 10.80.
    | May 12, 2014, 5:52 PM
  • May 12, 2014, 4:18 PM
    • McKesson (MCK): FQ4 EPS of $2.55 beats by $0.15.
    • Revenue of $38.1B (+24.4% Y/Y) beats by $2.21B.
    • Shares +2.2%.
    | May 12, 2014, 4:18 PM
  • May 12, 2014, 8:37 AM
    • Celesio's (CAKFF) Q1 EBIT nudges up to €95.6M from €95.1M a year earlier as revenue rises 0.3% to €5.38B.
    • The company, which was recently bought by McKesson (MCK), forecast that the "unremittingly intensive discount competition in Germany" will diminish in H2. As such, Celesio expects 2014 EBIT to grow slightly from last year. (PR)
    | May 12, 2014, 8:37 AM
  • May 11, 2014, 5:35 PM
    | May 11, 2014, 5:35 PM | 3 Comments
  • Mar. 18, 2014, 8:01 AM
    • Celesio (CAKFF), which is being acquired by McKesson (MCK), forecasts that it's adjusted EBIT will return to slight growth in 2014 as the drugs distributor expands its pharmacy network.
    • Celesio's EBIT fell 4.8% to €423.6M in 2013, due to pricing pressure in Germany and currency fluctuations.
    • Revenue -3.9% to €21.4B.
    • Net profit €166.4M vs a loss of €149M. (PR)
    | Mar. 18, 2014, 8:01 AM
  • Mar. 12, 2014, 12:16 PM
    • Goldman Sachs analyst Robert Jones adds his Buy-rated McKesson (MCK) to the firm's list of projected market-beating picks.
    • MCK's recent acquisition of Celesio is the main reason for his enhanced outlook.
    • His EPS estimates for 2014 and 2015 are $8.21 and $11.40, respectively. The consensus targets are $8.18 and $10.69.
    | Mar. 12, 2014, 12:16 PM
  • Feb. 28, 2014, 3:29 PM
    • McKesson (MCK +1%) is making more changes to its executive compensation program, and CEO John Hammergren is voluntarily reducing his pension benefit by $45M, after activist investors complained about the company's pay structure.
    • Hammergren's pension benefit still amounts to $114M after the reduction, but it will be a fixed amount in cash that's not subject to big potential moves that can result from changes in company assumptions about interest rates or other issues.
    • Critics say the moves are welcome but not enough; the company's executive pension plan is still "the richest in corporate America," says one governance analyst.
    • Separately, MCK says it has launched a voluntary takeover offer for the remaining shares outstanding of Celesio (CAKFF) for €23.50/share ($32.44); MCK, which owns more than 75% of Celesio's shares, last month received the necessary support to acquire its German rival after facing earlier opposition.
    | Feb. 28, 2014, 3:29 PM
  • Feb. 18, 2014, 10:42 AM
    • Rite Aid (RAD +5.8%) and McKesson (MCK +1.2%) say they have expanded an agreement to distribute drugs together.
    • The new pact will see more generic drugs flow through McKesson to Rite Aid stores.
    • Financial details of the 5-year deal weren't disclosed.
    | Feb. 18, 2014, 10:42 AM | 1 Comment
  • Jan. 30, 2014, 4:16 PM
    • McKesson Corporation (MCK): FQ3 EPS of $1.45 misses by $0.38.
    • Revenue of $34.3B (+10.0% Y/Y) misses by $4.27B.
    | Jan. 30, 2014, 4:16 PM
  • Jan. 30, 2014, 12:10 AM
  • Jan. 29, 2014, 5:35 PM
  • Jan. 29, 2014, 4:44 PM
    • McKesson Corporation (MCK) declares $0.24/share quarterly dividend, in line with previous.
    • Forward yield 0.55%
    • Payable April 1; for shareholders of record March 3; ex-div Feb. 27.
    | Jan. 29, 2014, 4:44 PM
  • Jan. 23, 2014, 5:07 PM
    • McKesson (MCK) reaches an agreement to buy Celesio (CAKFF) just 10 days after a failed tender offer for the rival company.
    • MCK acquires majority owner Franz Haniel & Cie's entire holding in Celesio for €23.50/share, the same price as its previous bid, and purchases Celesio convertible bonds from hedge fund Elliott Management; the moves provide MCK with more than 75% ownership of Celesio’s shares.
    • MCK has been seeking to expand, and Celesio has 132 wholesale branches supplying 65,000 pharmacies and hospitals across Europe.
    • MCK +2.9% AH.
    | Jan. 23, 2014, 5:07 PM
  • Jan. 23, 2014, 8:17 AM
    • Franz Haniel & Cie, which owns 50.01% in Celesio (CAKFF), could be trying to revive the sale of the German drug distributor to Mckesson (MCK) after the U.S. company fell short of gaining shareholder acceptance for the deal last week.
    • Reuters reports that Haniel has offered Elliott €23.50 for its shares - the same amount that Mckesson bid - although it's not clear how much Haniel would pay for the hedge fund's convertible bonds in Celesio.
    • It's also not clear if Haniel is acting as an intermediary for McKesson.
    • On a fully diluted basis, including convertibles, Haniel owns 41.8% in Celesio and Elliot 26.7%.
    • McKesson needed shareholder acceptance representing 75% of Celesio's voting rights for its bid to be authorized.
    | Jan. 23, 2014, 8:17 AM
Company Description
McKesson Corporation distributes pharmaceuticals, medical supplies and healthcare information technology that make healthcare safer while reducing costs.
Sector: Services
Industry: Drugs Wholesale
Country: United States